Development of an intraluminal device for the treatment of aortic regurgitation: Prototype and in vitro testing system

被引:1
作者
Ashton, RC
Goldstein, DJ
DAlessandro, D
Weinberg, AD
Burkhoff, D
Rosskothen, HD
Lemole, GM
Oz, MC
机构
[1] COLUMBIA UNIV COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032
[2] COLUMBIA UNIV COLL PHYS & SURG,DEPT CIRCULATORY PHYSIOL,NEW YORK,NY 10032
[3] ALLEGHENY GEN HOSP,DEPT SURG,PITTSBURGH,PA 15212
[4] MED CTR DELAWARE,DIV CARDIOTHORAC SURG,NEWARK,DE
关键词
D O I
10.1016/S0022-5223(96)70098-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Development of an intraluminal device to reduce aortic regurgitation could provide a strategy intermediate between medical treatment and aortic valve replacement, An initial prototype and a testing system have been designed. Methods: Aortic valves obtained from heart transplant recipients were explanted and assessed in a mock circulatory loop with resistive and capacitive elements, including pressure-flow characteristics, similar to those of a normal arterial system. Normal heart function was simulated by a pulsatile ventricular-assist device, Pressure on each side of the valve and flow through the valve were recorded, allowing the calculation of regurgitant fractions and transvalvular gradients, Six solid geometrically differing obturators were tested, Results: All six designs resulted in significant reduction in aortic regurgitation (p < 0.0001), ranging from 15% to 38% improvement compared with control values. Small increases in transvalvular gradients (from 0 to 7 mm Hg) were also noted. Discussion: initial results suggest that an intraluminally placed obturator can reduce aortic regurgitation without creating clinically significant transvalvular gradients. These initial in vitro experiments demonstrate the feasibility of an intraluminal device for the treatment of aortic valve disease, and further investigation is warranted.
引用
收藏
页码:979 / 983
页数:5
相关论文
共 20 条
[1]  
*AM HEART ASS, 1995, HEART STROK FACTS 19
[2]   TRANSLUMINAL IMPLANTATION OF ARTIFICIAL-HEART VALVES - DESCRIPTION OF A NEW EXPANDABLE AORTIC-VALVE AND INITIAL RESULTS WITH IMPLANTATION BY CATHETER TECHNIQUE IN CLOSED CHEST PIGS [J].
ANDERSEN, HR ;
KNUDSEN, LL ;
HASENKAM, JM .
EUROPEAN HEART JOURNAL, 1992, 13 (05) :704-708
[3]   THE NATURAL-HISTORY OF ASYMPTOMATIC PATIENTS WITH AORTIC REGURGITATION AND NORMAL LEFT-VENTRICULAR FUNCTION [J].
BONOW, RO ;
ROSING, DR ;
MCINTOSH, CL ;
JONES, M ;
MARON, BJ ;
LAN, KKG ;
LAKATOS, E ;
BACHARACH, SL ;
GREEN, MV ;
EPSTEIN, SE .
CIRCULATION, 1983, 68 (03) :509-517
[4]   SERIAL LONG-TERM ASSESSMENT OF THE NATURAL-HISTORY OF ASYMPTOMATIC PATIENTS WITH CHRONIC AORTIC REGURGITATION AND NORMAL LEFT-VENTRICULAR SYSTOLIC FUNCTION [J].
BONOW, RO ;
LAKATOS, E ;
MARON, BJ ;
EPSTEIN, SE .
CIRCULATION, 1991, 84 (04) :1625-1635
[5]   ASYMPTOMATIC AORTIC REGURGITATION - INDICATIONS FOR OPERATION [J].
BONOW, RO .
JOURNAL OF CARDIAC SURGERY, 1994, 9 (02) :170-173
[6]  
BORETOS JW, 1977, Patent No. 4056854
[7]  
CHRISTAKIS GT, 1988, CIRCULATION, V78, P25
[8]  
ELAYDA MA, 1993, CIRCULATION, V88, P11
[9]   AORTIC-VALVE REPLACEMENT - DETERMINANTS OF OPERATIVE MORTALITY [J].
HE, GW ;
ACUFF, TE ;
RYAN, WH ;
DOUTHIT, MB ;
BOWMAN, RT ;
HE, YH ;
MACK, MJ .
ANNALS OF THORACIC SURGERY, 1994, 57 (05) :1140-1146
[10]  
Hufnafgel CA, 1952, B GEORGETOWN U MED C, V6, P60